At #IKCSEU26, Olivier Exertier highlighted the amazing contribution of patient representatives like @ikccorg.bsky.social and Asso ARTuR in designing EU‑funded programmes such as #CARE1Project.
@oncoalert.bsky.social
#KidneyCancerAssociation
@actionkidneycancer.bsky.social
@oncoalert.bsky.social
#KidneyCancerAssociation
@actionkidneycancer.bsky.social
April 17, 2026 at 9:25 AM
At #IKCSEU26, Olivier Exertier highlighted the amazing contribution of patient representatives like @ikccorg.bsky.social and Asso ARTuR in designing EU‑funded programmes such as #CARE1Project.
@oncoalert.bsky.social
#KidneyCancerAssociation
@actionkidneycancer.bsky.social
@oncoalert.bsky.social
#KidneyCancerAssociation
@actionkidneycancer.bsky.social
Insightful discussion at #IKCSEU Paris.
During the session on Molecular Biomarkers and Patient Stratification, Yann Vano shared how the CARE1 trial could help clarify whether PD‑L1 can be used as a decision tool in routine therapeutics.
#CARE1 @oncoalert.bsky.social #KidneyCancerAssociation
During the session on Molecular Biomarkers and Patient Stratification, Yann Vano shared how the CARE1 trial could help clarify whether PD‑L1 can be used as a decision tool in routine therapeutics.
#CARE1 @oncoalert.bsky.social #KidneyCancerAssociation
April 17, 2026 at 9:16 AM
Insightful discussion at #IKCSEU Paris.
During the session on Molecular Biomarkers and Patient Stratification, Yann Vano shared how the CARE1 trial could help clarify whether PD‑L1 can be used as a decision tool in routine therapeutics.
#CARE1 @oncoalert.bsky.social #KidneyCancerAssociation
During the session on Molecular Biomarkers and Patient Stratification, Yann Vano shared how the CARE1 trial could help clarify whether PD‑L1 can be used as a decision tool in routine therapeutics.
#CARE1 @oncoalert.bsky.social #KidneyCancerAssociation
#Eisai #digitalplatform #kidneycancerpatients #kidneycancer #digitaldestination #Kompass #kidneycancerdiagnosis #KidneyCancerKompass #patientorganisations #KCCure #KidneyCAN #KidneyCancerAssociation #NationalKidneyFoundation #Lenvima #lenvatinib #MSD #renalcellcarcinoma #RCC
zurl.co/qpSNo
zurl.co/qpSNo
Eisai unveils digital platform for kidney cancer patients
Eisai has launched a 'digital destination', called Kompass, that aims to support patients after they have been given a diagnosis of kidney cancer.
pharmaphorum.com
April 1, 2026 at 9:14 AM